Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$1.54
+6.2%
$1.40
$1.05
$5.17
$166.75M0.381.20 million shs622,965 shs
MannKind Corporation stock logo
MNKD
MannKind
$3.82
+5.5%
$4.17
$3.51
$7.63
$1.16B0.962.44 million shs3.52 million shs
Merus N.V. stock logo
MRUS
Merus
$54.51
+4.2%
$50.18
$33.19
$62.98
$3.77B1739,442 shs1.30 million shs
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$24.98
$24.58
$3.18
$25.00
$2.37B2.472.28 million shs218,200 shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$5.02
+3.3%
$4.47
$3.81
$6.37
$295.83M0.68603,524 shs703,151 shs
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-0.68%+2.84%-5.23%+19.83%+14.17%
MannKind Corporation stock logo
MNKD
MannKind
+2.26%+1.12%-17.35%-22.81%-32.84%
Merus N.V. stock logo
MRUS
Merus
-0.48%-0.63%-6.90%+32.28%-6.07%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00%0.00%0.00%0.00%0.00%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-0.61%+3.85%+5.42%+17.68%-7.78%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
2.6211 of 5 stars
3.62.00.00.02.61.70.6
MannKind Corporation stock logo
MNKD
MannKind
2.5268 of 5 stars
3.61.00.00.00.51.71.9
Merus N.V. stock logo
MRUS
Merus
2.0872 of 5 stars
3.61.00.00.02.32.50.0
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
4.3803 of 5 stars
3.82.00.04.20.63.31.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
3.11
Buy$9.71530.80% Upside
MannKind Corporation stock logo
MNKD
MannKind
3.29
Buy$10.33170.51% Upside
Merus N.V. stock logo
MRUS
Merus
3.14
Buy$84.6455.27% Upside
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.00
N/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
3.50
Strong Buy$16.50228.69% Upside

Current Analyst Ratings Breakdown

Latest MRUS, MNKD, VNDA, PRVB, and ACRS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/23/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$8.00
5/28/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$8.00
5/23/2025
Merus N.V. stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus N.V. stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/14/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $16.00
5/14/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight$13.00
5/13/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/9/2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $9.00
5/8/2025
Merus N.V. stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/7/2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00 ➝ $20.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
$17.78M9.38N/AN/A$1.44 per share1.07
MannKind Corporation stock logo
MNKD
MannKind
$297.60M3.90$0.15 per share25.51($0.29) per share-13.17
Merus N.V. stock logo
MRUS
Merus
$54.73M68.93N/AN/A$9.46 per share5.76
Provention Bio, Inc. stock logo
PRVB
Provention Bio
$12.90M183.54N/AN/A$1.40 per share17.84
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$198.77M1.49N/AN/A$9.24 per share0.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$132.07M-$1.39N/AN/AN/A-732.42%-30.73%-22.74%8/6/2025 (Estimated)
MannKind Corporation stock logo
MNKD
MannKind
$27.59M$0.1038.2016.61N/A10.12%-32.41%10.85%8/6/2025 (Estimated)
Merus N.V. stock logo
MRUS
Merus
-$215.33M-$4.08N/AN/AN/A-506.73%-35.99%-29.83%7/30/2025 (Estimated)
Provention Bio, Inc. stock logo
PRVB
Provention Bio
-$113.57M-$1.53N/AN/AN/A-880.69%-103.36%-69.08%N/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$18.90M-$0.75N/AN/AN/A-21.98%-8.30%-6.85%7/30/2025 (Estimated)

Latest MRUS, MNKD, VNDA, PRVB, and ACRS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.14N/AN/AN/A$1.34 millionN/A
8/6/2025Q2 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.04N/AN/AN/A$77.82 millionN/A
7/30/2025Q2 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.34N/AN/AN/A$54.77 millionN/A
5/14/2025Q1 2025
Merus N.V. stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/8/2025Q1 2025
MannKind Corporation stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/7/2025Q1 2025
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.55-$0.50+$0.05-$0.50$45.13 million$50.04 million
5/6/2025Q1 2025
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
-$0.19-$0.12+$0.07-$0.12$3.55 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/AN/AN/AN/AN/A
MannKind Corporation stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Merus N.V. stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Provention Bio, Inc. stock logo
PRVB
Provention Bio
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
N/A
5.06
5.06
MannKind Corporation stock logo
MNKD
MannKind
N/A
2.36
2.11
Merus N.V. stock logo
MRUS
Merus
N/A
5.86
5.86
Provention Bio, Inc. stock logo
PRVB
Provention Bio
0.19
1.93
1.92
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/A
3.93
3.91

Institutional Ownership

CompanyInstitutional Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
98.34%
MannKind Corporation stock logo
MNKD
MannKind
49.55%
Merus N.V. stock logo
MRUS
Merus
96.14%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
37.39%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
6.40%
MannKind Corporation stock logo
MNKD
MannKind
2.70%
Merus N.V. stock logo
MRUS
Merus
4.57%
Provention Bio, Inc. stock logo
PRVB
Provention Bio
13.10%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
8.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Aclaris Therapeutics, Inc. stock logo
ACRS
Aclaris Therapeutics
100108.28 million101.35 millionOptionable
MannKind Corporation stock logo
MNKD
MannKind
400303.93 million294.82 millionOptionable
Merus N.V. stock logo
MRUS
Merus
3769.21 million66.05 millionOptionable
Provention Bio, Inc. stock logo
PRVB
Provention Bio
8294.78 million82.37 millionNot Optionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
29058.93 million53.69 millionOptionable

Recent News About These Companies

VNDA - Vanda Pharmaceuticals Inc Chart - Morningstar
Brokers Issue Forecasts for VNDA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

Aclaris Therapeutics stock logo

Aclaris Therapeutics NASDAQ:ACRS

$1.54 +0.09 (+6.21%)
Closing price 04:00 PM Eastern
Extended Trading
$1.58 +0.03 (+2.27%)
As of 05:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

MannKind stock logo

MannKind NASDAQ:MNKD

$3.82 +0.20 (+5.52%)
Closing price 04:00 PM Eastern
Extended Trading
$3.77 -0.05 (-1.28%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Merus stock logo

Merus NASDAQ:MRUS

$54.51 +2.18 (+4.17%)
Closing price 04:00 PM Eastern
Extended Trading
$54.50 0.00 (-0.01%)
As of 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Provention Bio stock logo

Provention Bio NASDAQ:PRVB

Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn's disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$5.02 +0.16 (+3.29%)
Closing price 04:00 PM Eastern
Extended Trading
$5.06 +0.04 (+0.80%)
As of 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.